Myomo, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022 and Full Year of 2023
November 10, 2022 at 09:05 pm
Share
Myomo, Inc. provided revenue guidance for the fourth quarter of 2022 and full year of 2023. The company expects to be able to report modest sequential product revenue growth in the fourth quarter.
The company expects to enter 2023 with a much larger pipeline than it entered 2022, positioning the Company for stronger product revenue growth in 2023.
Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. It develops and markets the MyoPro product line. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. MyoPro senses a patientâs own electromyography (EMG) signals through non-invasive sensors on the arm, and can restore an individualâs ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. It provides devices directly to patients and bill their insurance companies directly. It also sells its products through various other sales channels, including through orthotics and prosthetics providers, the veteranâs administration, and others.
MYOMO, INC. 
